FDA Approves Guardant360 CDx for Breast Cancer
Analysis based on 9 articles · First reported Sep 04, 2026 · Last updated Sep 06, 2026
The approval strengthens Guardant Health's position in precision oncology and expands the market for its liquid biopsy platform, likely boosting revenue and investor confidence. AstraZeneca benefits from a broader patient population eligible for ETCAMAH, potentially increasing drug sales and reinforcing its oncology portfolio.
The U.S. United States — Food and Drug Administration approved Guardant Health's Guardant360 CDx as a companion diagnostic to identify patients with HR-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations before radiographic progression, who may benefit from treatment with AstraZeneca's ETCAMAH (camizestrant). This is the first FDA-approved liquid biopsy CDx for longitudinal testing in breast cancer, enabling adaptive cancer management through pre-radiographic ctDNA testing. The approval is based on data from the pivotal SERENA-6 trial, which showed a 56% reduction in risk of progression or death for patients switched to camizestrant upon ESR1 mutation detection. This marks the 29th CDx indication for Guardant360 CDx globally.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard